American Century Companies’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-4,626
Closed -$421K 2845
2023
Q2
$421K Sell
4,626
-226,628
-98% -$19.6M ﹤0.01% 2290
2023
Q1
$15.2M Buy
231,254
+430
+0.2% +$24.8K 0.01% 859
2022
Q4
$11.9M Buy
230,824
+215,553
+1,412% +$11.4M 0.01% 904
2022
Q3
$1.04M Sell
15,271
-1,495
-9% -$88.5K ﹤0.01% 1677
2022
Q2
$758K Buy
16,766
+188
+1% +$8.57K ﹤0.01% 1753
2022
Q1
$820K Buy
+16,578
New +$732K ﹤0.01% 1749

Other funds holding APLS

American Century Companies's APLS Position: Q3 2023 in Review

American Century Companies sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 4,626 shares — an estimated $421K sold.

American Century Companies first reported a position in APLS in Q1 2022 and held it in 6 quarters. The position peaked at $15.2M in Q1 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • American Century Companies reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • American Century Companies sold 4,626 Apellis Pharmaceuticals shares in Q3 2023, an estimated $421K.
  • American Century Companies first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • American Century Companies's Apellis Pharmaceuticals position peaked at $15.2M in Q1 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on American Century Companies's 13F filing for Q3 2023, filed 13 Nov 2023.